Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML1522

Sigma-Aldrich

Doxofylline

≥98% (HPLC)

Synonym(s):

7-(1,3-Dioxolan-2-ylmethyl)-1,3-dimethylpurine-2,6-dione, 7-(1,3-Dioxolan-2-ylmethyl)theophylline

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C11H14N4O4
CAS Number:
69975-86-6
Molecular Weight:
266.25
MDL number:
MFCD00865218
UNSPSC Code:
12352200
PubChem Substance ID:
329825939
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

H2O: 2 mg/mL, clear (warmed)

storage temp.

2-8°C

SMILES string

CN1C2=C(N(CC3OCCO3)C=N2)C(N(C)C1=O)=O

InChI

1S/C11H14N4O4/c1-13-9-8(10(16)14(2)11(13)17)15(6-12-9)5-7-18-3-4-19-7/h6-7H,3-5H2,1-2H3

InChI key

HWXIGFIVGWUZAO-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

Doxofylline is a novel xanthine derivative comprising of dioxolone group.

Application

Doxofylline has been used as a phosphodiesterase (PDE) inhibitor to study its protective effects on lipopolysaccharides (LPS)-induced inflammatory response in human pulmonary bronchial epithelial cells. It has also been used to study its interaction with bovine serum albumin (BSA).

Biochem/physiol Actions

Doxofylline (also known as doxophylline) has antitussive and bronchodilator effects. Doxofylline is used clinically in the treatment of asthma. Doxofylline has similar efficacy to theophylline, but unlike theophylline or other xanthines has little affinity for adenosine receptors and does not produce stimulant effects and has significantly fewer side effects.
Doxofylline acts and as a non-selective phosphodiesterase (PDE) inhibitor and exhibits anti-inflammatory activity. It has the potential to treat chronic obstructive pulmonary disease (COPD).

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302

Precautionary Statements

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Dali Shukla et al.
Expert opinion on pharmacotherapy, 10(14), 2343-2356 (2009-08-15)
Doxofylline, a methylxanthine derivative, has recently drawn attention because of its better safety profile and similar efficacy over the most widely prescribed analogue, theophylline, indicated for asthma and chronic obstructive pulmonary disease. This article attempts to discuss the pharmacodynamics/pharmacokinetics and
Peng Jiao et al.
Artificial cells, nanomedicine, and biotechnology, 48(1), 687-694 (2020-02-27)
Lung diseases are common health problems in many countries. The dysfunction of bronchial epithelial cells is important for the development of lung diseases. Recent progress reveals that inflammasome is the fundamental mechanism of epithelial activation. Here, we report the protective
Sharmin Siddiqui et al.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 249, 119296-119296 (2020-12-19)
Insight into the mechanistic binding of bovine serum albumin (BSA) with doxofylline can layout pivotal enlightenment with relevance to pharmacokinetics and pharmacodynamics properties. Herein, many spectroscopic techniques and computational methods had been employed to interpret the structural and binding dynamics
Muhasaparur Ganesan Rajanandh et al.
Clinical therapeutics, 37(2), 418-426 (2015-01-13)
Data comparing various second-line treatments for asthma with subjective and objective assessment are lacking. This study aimed to compare the efficacy and safety of montelukast, doxofylline, and tiotropium with a low-dose budesonide in patients with mild to moderate persistent asthma.
Dushyant Lal et al.
Journal of basic and clinical physiology and pharmacology, 26(5), 443-451 (2015-04-22)
Bronchial asthma and chronic obstructive pulmonary disease (COPD) are the major obstructive disorders that may contribute to the severity in individual patients. The present study was designed to compare the efficacy and safety of theophylline and doxofylline in patients with
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service